Department of Neurosciences, University of California San Diego, CA, USA.
Alzheimers Dement. 2010 May;6(3):239-46. doi: 10.1016/j.jalz.2010.03.006.
The Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has provided clinical, operational, and data management support to ADNI since its inception. This article reviews the activities and accomplishments of the core in support of ADNI aims. These include the enrollment and follow-up of more than 800 subjects in the three original cohorts: healthy controls, amnestic mild cognitive impairment (now referred to as late MCI, or LMCI), and mild Alzheimer's disease (AD) in the first phase of ADNI (ADNI 1), with baseline longitudinal, clinical, and cognitive assessments. These data, when combined with genetic, neuroimaging, and cerebrospinal fluid measures, have provided important insights into the neurobiology of the AD spectrum. Furthermore, these data have facilitated the development of novel clinical trial designs. ADNI has recently been extended with funding from an NIH Grand Opportunities (GO) award, and the new ADNI GO phase has been launched; this includes the enrollment of a new cohort, called early MCI, with milder episodic memory impairment than the LMCI group. An application for a further 5 years of ADNI funding (ADNI 2) was recently submitted. This funding would support ongoing follow-up of the original ADNI 1 and ADNI GO cohorts, as well as additional recruitment into all categories. The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations.
阿尔茨海默病神经影像学倡议（ADNI）的临床核心自成立以来一直为 ADNI 提供临床、运营和数据管理支持。本文回顾了核心在支持 ADNI 目标方面的活动和成就。这些活动包括在 ADNI1 的第一阶段招募和随访超过 800 名受试者，这些受试者分为三个原始队列：健康对照者、遗忘型轻度认知障碍（现在称为晚期 MCI，或 LMCI）和轻度阿尔茨海默病（AD），基线时进行纵向、临床和认知评估。这些数据与遗传、神经影像学和脑脊液测量相结合，为 AD 谱的神经生物学提供了重要的见解。此外，这些数据还促进了新型临床试验设计的发展。ADNI 最近获得了 NIH 大机遇（GO）拨款的扩展，并启动了新的 ADNI GO 阶段；这包括招募一个新的队列，称为早期 MCI，其情节记忆障碍比 LMCI 组更轻微。最近提交了一份 ADNI 2 年资金申请。这项资助将支持对原始 ADNI1 和 ADNI GO 队列的持续随访，以及对所有类别的额外招募。由此产生的数据将提供有关 AD 最早阶段的宝贵数据，并支持在这些至关重要的人群中开展干预措施。
